Biblio
Export 57 results:
Author Title Type [ Year] Filters: Author is Zetterberg, Henrik [Clear All Filters]
“Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
, ,
“Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1395-1408, 2016.
, “Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.”, J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
, “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
, “Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.”, J Alzheimers Dis, vol. 52, no. 1, pp. 51-64, 2016.
, “Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?”, J Alzheimers Dis, vol. 54, no. 4, pp. 1297-1302, 2016.
, “A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1353-63, 2016.
, “Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.”, J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
, “Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.”, J Alzheimers Dis, vol. 52, no. 4, pp. 1373-83, 2016.
, “Specific Triazine Herbicides Induce Amyloid-β42 Production.”, J Alzheimers Dis, vol. 54, no. 4, pp. 1593-1605, 2016.
, “The Vanderbilt Memory & Aging Project: Study Design and Baseline Cohort Overview.”, J Alzheimers Dis, vol. 52, no. 2, pp. 539-59, 2016.
, “Alterations in the Balance of Amyloid-β Protein Precursor Species in the Cerebrospinal Fluid of Alzheimer's Disease Patients.”, J Alzheimers Dis, vol. 57, no. 4, pp. 1281-1291, 2017.
, “Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.”, J Alzheimers Dis, vol. 58, no. 3, pp. 821-828, 2017.
, “Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
, “Comprehensive Quantitative Profiling of Tau and Phosphorylated Tau Peptides in Cerebrospinal Fluid by Mass Spectrometry Provides New Biomarker Candidates.”, J Alzheimers Dis, vol. 55, no. 1, pp. 303-313, 2017.
, “Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration.”, J Alzheimers Dis, vol. 56, no. 3, pp. 885-891, 2017.
, “Inflammation, Amyloid, and Atrophy in The Aging Brain: Relationships with Longitudinal Changes in Cognition.”, J Alzheimers Dis, vol. 58, no. 3, pp. 829-840, 2017.
, “Intracranial Arterial 4D Flow in Individuals with Mild Cognitive Impairment is Associated with Cognitive Performance and Amyloid Positivity.”, J Alzheimers Dis, vol. 60, no. 1, pp. 243-252, 2017.
, “Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization.”, J Alzheimers Dis, vol. 55, no. 1, pp. 159-170, 2017.
, “Pathway-Specific Polygenic Risk Scores as Predictors of Amyloid-β Deposition and Cognitive Function in a Sample at Increased Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 473-484, 2017.
, “PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers.”, J Alzheimers Dis, vol. 60, no. 1, pp. 283-293, 2017.
, “Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease.”, J Alzheimers Dis, vol. 58, no. 4, pp. 1245-1254, 2017.
, “Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium.”, J Alzheimers Dis, vol. 55, no. 1, pp. 371-379, 2017.
, “Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 59, no. 3, pp. 1017-1026, 2017.
,